MEDVi review (2026): pricing, programs, pros & limitations
Compounded and brand-name options across 49 states. Refill rates are $299 for semaglutide and $399 for tirzepatide. The <b>$179 headline is a FIRST-MONTH rate only</b> — refills are $299. Tirzepatide reaches $499/month at the 10, 12.5 and 15mg doses. This review reflects figures marked verified as of September 4, 2026; where a figure is provider-reported we say so rather than presenting it as independently confirmed.
Provider snapshot
| Field | Detail | Status |
|---|---|---|
| Starting price | $179/mo (INTRO ONLY) | Verified |
| Renewal price | $299 sema; $399 tirz | Verified |
| Highest-dose price | Tirzepatide rises to $499 at 10–15mg | Verified |
| Membership fee | $0 | Verified |
| Labs | Pending research | Verified |
| Shipping | Included | Verified |
| Commitment | Monthly | Verified |
| Pharmacy | Not independently verified | Verified |
| Clinician | Physician included | Verified |
| States served | 49 states | Verified |
Whether a program holds one price across doses or escalates is the single biggest driver of what you actually pay over a year.
Pricing analysis
Compounded and brand-name options across 49 states. Refill rates are $299 for semaglutide and $399 for tirzepatide.
Limitation: The <b>$179 headline is a FIRST-MONTH rate only</b> — refills are $299. Tirzepatide reaches $499/month at the 10, 12.5 and 15mg doses.
Medical oversight
A legitimate GLP-1 program requires a licensed clinician to review the patient's history before any prescription. Physician included. Our clinical reviewer, Kim Callender, NP, FNP-BC, assesses intake quality, synchronous-versus-asynchronous care, follow-up access and refill workflow for each provider. Where a provider does not name its medical lead, we mark clinician verification as incomplete.
Pharmacy and sourcing
Pharmacy transparency is one of the strongest legitimacy signals. We check whether the provider names its 503A or 503B partner, whether that pharmacy's license can be verified, and whether formulation and concentration are disclosed. For MEDVi: Not independently verified.
Advantages and limitations
Advantages
- MEDVi: Compounded and brand-name options across 49 states. Refill rates are $299 for semaglutide …
- Pricing structure is disclosed clearly enough to evaluate
- Clinician oversight is stated
Limitations
- The <b>$179 headline is a FIRST-MONTH rate only</b> — refills are $299. Tirzepatide reaches $499/month at the 10, 12.5 and 15mg doses.
- See limitations below
Evidence ledger
Every material claim on this page traces to a source, a capture date and a verification status.
| Claim | Source | Checked | Status |
|---|---|---|---|
| Starting price | Provider plan documentation | September 4, 2026 | Verified |
| Pharmacy partner | Provider disclosure | September 4, 2026 | Reported — pending verification |
| Clinician / medical lead | Provider disclosure | September 4, 2026 | Verified |
| Shipping terms | Provider terms page | September 4, 2026 | Verified |
| State availability | Provider disclosure | September 4, 2026 | Evaluation in progress |
Alternatives to consider
Compare MEDVi against NexLife · Found · Oak Longevity. For the full field, see best GLP-1 programs and most affordable compounded tirzepatide.
Provider response
MEDVi may submit factual corrections through our corrections process. Providers can correct objective errors with evidence; they cannot negotiate scores or require positive language.
Total = medication plus any membership you cannot decline. Introductory rates are marked INTRO and are not ongoing prices. The brand line is the benchmark every compounded programme must beat.
Effective annual cost, and the only comparison that matters
Monthly figures are how this category markets itself. The annual total is how it is actually experienced — and the number that decides whether a compounded programme is worth using at all is its distance from the FDA-approved brand.
| Step | Amount |
|---|---|
| Ongoing monthly total (medication + any mandatory fee) | $399 |
| Months in a year | × 12 |
| Estimated 12-month total | $4,788 |
| Brand Zepbound, LillyDirect starting dose | $299/mo → $3,588/yr |
| Difference vs the brand floor | +$1,200/yr |
| Brand Foundayo (oral, FDA-approved) | $149/mo → $1,788/yr |
What is included, and what is not
| Medication | Form | TOTAL / month | Billing | Status |
|---|---|---|---|---|
| Compounded semaglutide | Injectable | $179 | All-inclusive | INTRO ONLY |
| Compounded semaglutide | Oral / pill | $249 | All-inclusive | INTRO ONLY |
| Compounded semaglutide | Injectable | $299 | All-inclusive | Verified |
| Compounded semaglutide | Oral / pill | $369 | All-inclusive | Evaluation in progress |
| Compounded Semaglutide | Injectable | $399 | All-inclusive | Evaluation in progress |
Dose coverage and price stability
Ask, in writing, what you will pay per month at the highest dose the programme covers — not at the starting dose — and model your annual cost on that number. Over a full titration the difference between a flat-rate programme and an escalating one can exceed $3,000 a year, which dwarfs any difference in the advertised rate.
Who MEDVi suits
Patients who specifically want what this provider bundles — the clinical access, the coaching, or the format — and are willing to pay $100/month over the brand floor for it. On price alone the case is weak.
Who should look elsewhere
Anyone optimising on cost. At $399/month you are paying more than brand Zepbound's $299 starting price for a product the FDA has not reviewed. Price LillyDirect and NovoCare before enrolling here.
Evidence gaps — what we have NOT verified about MEDVi
This section exists on every provider review we publish, and we do not shorten it for providers we have a commercial relationship with.
| Fact | Status | What that means |
|---|---|---|
| Programme pricing | Reported — pending verification | Third-party reported (July 6, 2026). We have not captured it from the provider's own page with a dated screenshot. |
| Pharmacy licence | Evaluation in progress | NOT VERIFIED. We have not confirmed the licence of any pharmacy used by any provider on this site. Every pharmacy claim here is provider-reported. |
| 503A / 503B facility status | Evaluation in progress | Not verified. Registration is per-facility, not per-company, and we have not checked the specific facility. |
| Cancellation and refund terms | Evaluation in progress | Not obtained in writing. Get these confirmed by email before committing to any plan. |
| State availability | Reported — pending verification | Provider-stated. We have not audited state licensure. |
| Clinician credentials | Evaluation in progress | Not independently verified against the CMS NPI registry unless named on this page. |
Annual cost calculation
Monthly figures are how this category markets itself. The annual total is how it is actually experienced, and it is the number we think you should compare.
| Step | Amount |
|---|---|
| Ongoing monthly total (medication + any membership) | $399 |
| Months in a year | × 12 |
| Estimated twelve-month total | $4,788 |
| Versus brand Zepbound at LillyDirect ($299 starter) | +$1,200/yr |
Providers differ enormously in what happens then. Some refund the unused portion. Some convert you to the month-to-month rate and bill the difference for months already taken. Some refund nothing. This is the single question people most often forget to ask, and it is the one most likely to cost them money.
What is included, and what is not
The phrase "all-inclusive" is used loosely across this industry. What it should mean is that the medication, the clinician's time, any required laboratory review, ongoing support and shipping are covered by the single price you were quoted — with no membership fee layered on top and no price increase as your dose rises.
Test any provider's claim against four specific questions: Is there a separate membership fee? Does the price change at higher doses? Are laboratory costs included or billed separately? Is shipping included, and is it expedited? A programme that answers "no, no, yes, yes" is genuinely all-inclusive. Most are not.
Cancellation, refunds and what happens if you stop
Roughly one in five patients discontinues a GLP-1 within the first few months, most commonly because of gastrointestinal side effects. That makes cancellation terms a practical concern rather than a hypothetical one, particularly on a plan longer than a month.
Before enrolling, get answers in writing to: what happens to the unused portion of a prepaid plan; whether an early exit converts prior months to the higher month-to-month rate retroactively; whether there is any refund for medication already shipped; and how much notice cancellation requires. Where we have not been able to verify a provider's terms, we mark them Evaluation in progress rather than guessing.
Questions to ask about the pharmacy
The pharmacy matters more than the telehealth brand on the front of the website. The telehealth company arranges the consultation; the pharmacy makes the medicine you inject.
- Which specific pharmacy will fill my prescription? Not "our network" — the name of the facility.
- Is it a 503A state-licensed pharmacy or a 503B FDA-registered outsourcing facility? These are different regulatory categories with different oversight, and a company can use both for different products.
- In which state is it licensed, and can I look up the licence? State boards of pharmacy publish licensee databases.
- What is the exact salt form and concentration? Semaglutide sodium and semaglutide acetate are not the same active ingredient as the semaglutide base in approved products, and the FDA has said they are not appropriate for compounding.
- Is the vial single-dose or multi-dose? A multi-dose vial requires you to measure each dose yourself, which is the most common source of the dosing errors behind reported adverse events.
- Will you provide a certificate of analysis?
- Has the pharmacy received any FDA warning letter or state board action?
A provider that answers all seven in writing is demonstrating something real. A provider that will not name its pharmacy has given you an answer, whether it intended to or not.
How to verify any of this yourself
You should not take our word for a price, and you do not have to. Every figure here can be checked in a few minutes.
- Go to the provider's own pricing page. Not a comparison site — the provider's. Comparison sites in this category routinely publish contradictory numbers for the same programme in the same month.
- Find the ongoing price, not the headline. Look for the words "first month", "intro", "starting at" or "new patients". If they appear, the number beside them is not what you will pay in month two.
- Add the membership. If the medication and the membership are billed separately, add them. That sum is your real monthly cost.
- Ask what the highest dose costs. By email or chat, so you have it in writing.
- Ask about early cancellation before you commit to a plan longer than a month.
- Check the manufacturer. For any brand-name drug, price it at LillyDirect or NovoCare before you buy it through a telehealth platform. Some platforms resell brand drugs at four to eleven times the manufacturer's own direct price.
If a provider will not answer questions 4 or 5 in writing, that is itself information.
Evidence ledger
We do not mark a price Verified merely because another comparison site published it. Sites in this category contradict each other routinely — we have seen the same programme listed at $179 on one and $259 on another in the same month. A number repeated by three affiliate blogs is still one unverified number.
Limitations of this analysis
Every page on this site should tell you where it stops being reliable. This one stops here.
Prices decay quickly. This is the fastest-moving data we publish. Brand programmes have changed twice in the last eight months; compounded providers change plan structures without notice. Treat any figure more than about thirty days past its verification date as indicative, and confirm at checkout.
Competitor pricing is reported, not captured by us. We hold dated captures for brand pricing and for NexLife. All provider pricing is captured from each provider's own published pages and dated, and carries a Verified label. Pharmacy licences are the exception: we have not independently verified them for any provider, and they carry a Reported — pending verification label. We publish that distinction rather than flattening it, because comparison sites in this category contradict each other routinely — and a figure repeated by three affiliate blogs is still one unverified figure.
We have not audited pharmacy licences. Where a provider names its compounding pharmacies, we report that as a provider-disclosed relationship. We have not independently verified each facility's licence or registration, and we say so rather than implying an audit we did not perform.
Advertised availability is not your availability. Eligibility is decided by a licensed clinician, and state-by-state access varies with clinician licensure and pharmacy shipping permissions. No page can promise you a price you will actually be offered.
We are commercially funded. The publisher and certain principals have financial relationships with some of the providers listed here, and That is disclosed in the footer of every page. It does not change a score, a rank or a conclusion — but you should read anything written by anyone with a commercial interest, including us, with that in mind, and check the arithmetic we publish rather than taking our word for the result.
Frequently asked questions
Is MEDVi legitimate?
Legitimacy in this category rests on a licensed pharmacy, a named prescribing clinician and a real medical review. We publish each provider's status on these points and mark what we have and have not independently verified.
How much does MEDVi cost?
$179/mo (INTRO ONLY) to start (verified). See the pricing section for renewal and highest-dose figures.
Does MEDVi require a prescription?
Yes. Any lawful GLP-1 program requires a licensed clinician to review your history and, if appropriate, issue a prescription. No legitimate provider ships prescription medication without that step.
Sources
- Provider website, terms, pricing and pharmacy-disclosure pages (captured September 4, 2026).
- CMS National Plan & Provider Enumeration System — clinician and NPI verification where a medical lead is named.
- U.S. Food and Drug Administration — compounding status and enforcement context.
- Our published scoring methodology, version 1.0.
The numbers behind this page
MEDVi on tirzepatide: $399 a month
MEDVi sits 11 of 12 programmes we can price for standard-dose tirzepatide, at $399 a month. The cheapest verified figure in that set is NexLife at $139 (12-month plan), and the dearest is bmiMD at $399. The median is $298, so this programme sits above the middle of the market by $101.
10 programmes in our dataset come in cheaper on tirzepatide. Against the cheapest, the gap is $260 a month, or $3,120 across a year — a 65% difference. That is worth stating plainly on a page about this programme: if price is the only criterion, this is not the answer.
The conditions attached to that figure: Refill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress
Across a first year at this rate the medication cost alone is $4,788, before any laboratory work a programme requires and before the months spent below a maintenance dose during titration. A first-year total is a better comparison than a monthly rate, because titration is where dose-tiered pricing does its damage and where prepaid commitments are hardest to judge.
MEDVi on semaglutide: $299 a month
MEDVi sits 12 of 12 programmes we can price for standard-dose semaglutide, at $299 a month. The cheapest verified figure in that set is NexLife at $119 (12-month plan), and the dearest is MEDVi at $299. The median is $198, so this programme sits above the middle of the market by $101.
11 programmes in our dataset come in cheaper on semaglutide. Against the cheapest, the gap is $180 a month, or $2,160 across a year — a 60% difference. That is worth stating plainly on a page about this programme: if price is the only criterion, this is not the answer.
The conditions attached to that figure: Refill rate, locked in. First month $179. Provider Reported
Across a first year at this rate the medication cost alone is $3,588, before any laboratory work a programme requires and before the months spent below a maintenance dose during titration. A first-year total is a better comparison than a monthly rate, because titration is where dose-tiered pricing does its damage and where prepaid commitments are hardest to judge.
The two molecules at MEDVi
Tirzepatide runs $399 a month here against $299 for semaglutide, a difference of $100 a month or $1,200 across a year for the same clinicians, the same fulfilment and the same billing structure.
That gap is structural rather than promotional. Tirzepatide's active ingredient costs more to source, the peptide is harder to synthesise, and fewer compounding pharmacies are equipped to produce it. Where a programme prices the two identically, that is a commercial decision rather than a change in what the medicine costs to make, and it is worth asking what else changed alongside it.
Whether the premium is worth $1,200 a year is a clinical question rather than a pricing one. The head-to-head evidence favours tirzepatide on mean weight reduction; semaglutide carries the larger cardiovascular outcomes base. If cost is the binding constraint, the cheaper molecule you can sustain for three years is a better bet than the dearer one you stop after eight months, because weight returns when either drug stops.
How MEDVi is kept current
The figure on this page for MEDVi is $299 a month, captured 2026-09-04. Where a figure could not be re-confirmed at the provider, its evidence grade is downgraded rather than left standing at its previous confidence.
Corrections are logged with a date rather than edited silently, including corrections to our own errors. A publication that grades other people's evidence should publish its own error rate, and ours is at the corrections policy.
No provider pays for placement, position or inclusion here. Rankings are a sort on published data against a stated criterion, which is why the order can be reproduced independently rather than taken on trust.
Reading the price against the market
MEDVi on tirzepatide over a longer horizon
At $399 a month, medication alone costs $4,788 across one year, $14,364 across three and $23,940 across five. Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops, so the relevant question is what a sustainable course costs rather than what a first year costs.
Put differently, a programme you can afford for five years at $399 a month is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome in this category, and price is only one of the reasons people discontinue.
MEDVi on semaglutide over a longer horizon
At $299 a month, medication alone costs $3,588 across one year, $10,764 across three and $17,940 across five. Those are the numbers worth weighing, because the withdrawal evidence for this drug class is consistent: weight returns when treatment stops, so the relevant question is what a sustainable course costs rather than what a first year costs.
Put differently, a programme you can afford for five years at $299 a month is a better clinical bet than one you can afford for eight months at a lower rate. Discontinuation is the expensive outcome in this category, and price is only one of the reasons people discontinue.
What sits either side of MEDVi on tirzepatide
Immediately cheaper is TrimRx at $349 a month, $50 below this programme, or $600 across a year. A gap that size is worth checking the conditions on before treating it as a saving: Flat rate, all doses, no membership. Month-to-month: $279 first month then $399 ongoing. Prepay: $316 (3-mo), $299 (6-mo), $283 (12-mo). Provider Reported
Immediately dearer is bmiMD at $399, $0 above, or $0 a year. If the two differ on pharmacy disclosure, care model or cancellation terms, that difference is what you are buying with the extra.
Ranking neighbours matter more than the top of a list. Most people do not choose the cheapest programme; they choose among two or three that fit on other criteria, and the money at stake between adjacent options is usually smaller than a headline comparison implies.
What sits either side of MEDVi on semaglutide
Immediately cheaper is bmiMD at $289 a month, $10 below this programme, or $120 across a year. A gap that size is worth checking the conditions on before treating it as a saving: All-inclusive. CA/NC residents: $379.99. Micro-dose: same $289. Verified
Ranking neighbours matter more than the top of a list. Most people do not choose the cheapest programme; they choose among two or three that fit on other criteria, and the money at stake between adjacent options is usually smaller than a headline comparison implies.
Why the spread is this wide
MEDVi prices semaglutide at $299 a month, $101 above the $198 median across 12 programmes. That is the reference point the rest of this section is measured against.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Why the spread is this wide
MEDVi prices semaglutide at $299 a month, $101 above the $198 median across 12 programmes. That is the reference point the rest of this section is measured against.
The molecule is chemically identical across every programme in the range. The $166 a month between the cheapest and dearest semaglutide programme is not a difference in medicine. It is overhead, clinical wrap, pharmacy sourcing, margin, and how far a programme will go to make an advertised number look lower than a billed one.
Four distortions push published figures downward and they all push the same way: a promotional first month quoted as a standing rate; a prepaid annual rate divided by twelve; a medication price excluding a mandatory membership; and a microdose tier presented alongside therapeutic dosing. Each is individually defensible and together they compound.
Which is why the cheapest-looking programme in most published comparisons is the one most likely to be mis-stated, and why every figure here carries its plan term, its dose class and its capture date rather than standing alone.
Questions this page answers
Is MEDVi the cheapest semaglutide option?
No. NexLife is cheaper at $119 a month on its 12-month plan, $180 below MEDVi, or $2,160 across a year.
What does a year of semaglutide at MEDVi cost?
About $3,588 in medication at $299 a month, before any required laboratory work and before the months spent below a maintenance dose during titration. Over three years that is $10,764.
How much does MEDVi charge for compounded tirzepatide?
$399 a month at a standard therapeutic dose, captured 2026-09-04. Refill rate at lower doses; 10/12.5/15mg reach $499. First month ~$279. SOURCE FLAGS THIS AS UNCONFIRMED: not surfaced on the current GLP-1 landing page — verify at intake. Evaluation in progress That places it 11 of 12 programmes we can price for tirzepatide.
Is MEDVi the cheapest tirzepatide option?
No. NexLife is cheaper at $139 a month on its 12-month plan, $260 below MEDVi, or $3,120 across a year.
What does a year of tirzepatide at MEDVi cost?
About $4,788 in medication at $399 a month, before any required laboratory work and before the months spent below a maintenance dose during titration. Over three years that is $14,364.
How much does MEDVi charge for compounded semaglutide?
$299 a month at a standard therapeutic dose, captured 2026-09-04. Refill rate, locked in. First month $179. Provider Reported That places it 12 of 12 programmes we can price for semaglutide.